ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 833

Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin

Scott Jenks1, Regina Bugrovsky1, Xiaoqian Wang1,2, Aisha Hill3, Chungwen Wei4, S. Sam Lim5, Ignacio Sanz6 and Cristina Drenkard5, 1Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, 2Division of Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, 3Medicine, Emory University School of Medicine, atlanta, GA, 4Medicine, Emory University School of Medicine, Atlanta, GA, 5Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 6Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-dsDNA, autoantibodies and cutaneous lupus erythematosus, B cell tolerance, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: While the contribution of humoral immunity to SLE is well established, the role it plays in chronic cutaneous lupus erythematosus (CCLE) is less clear. One characteristic of SLE is a breakdown of tolerance in autoreactive VH4.34 antibodies that are recognized by the rat anti-human idiotypic antibody 9G4 (9G4+). 9G4+ antibodies have germ line encoded autoreactive specificity for glycolipids found on red blood cells and B cells. Despite a high frequency of naive 9G4+ B cells, healthy control donors (HC) have low amounts of serum 9G4+ IgG. In contrast, many SLE patients have high levels of serum 9G4+ IgG that is associated with higher disease activity and highly correlated with anti-dsDNA and a substantial proportion of anti-dsDNA antibodies are 9G4+. The purpose of this study was to compare 9G4+ IgG and associated SLE auto-antibodies between CCLE patients and SLE patients.

Methods: We analyzed samples from 36 HC and 52 patients with primary CCLE, 44 SLE with CCLE, and 303 SLE without CCLE. Cases with a validated diagnosis of either discoid, panniculitis, tumidus or chilblain lupus were included as CCLE. The ACR criteria and attending rheumatologist/dermatologist judgement were used to classify CCLE cases as primary or associated with SLE. We used ELISA to measure 9G4 with the rat monoclonal 9G4, and goat anti-human IgG. Anti-dsDNA and anti-chromatin IgG were measured using commercial ELISA kits. B cell binding 9G4+ was evaluated ex-vivo by flow cytometry.

Results:

41% of SLE patients were positive for 9G4 IgG and had significantly higher serum concentration than HC (p<0.001) Surprisingly, CCLE patients also had high levels of 9G4+ IgG, 38% were positive and serum concentrations were significantly higher than HC (p<0.001) and did not statistically differ from SLE patients. In contrast, while many SLE patients had anti-dsDNA (48%) and anti-chromatin (52%), few CCLE patients were positive for these specificities (12% and 21%) and the concentration was significantly lower for both (p<0.001). Consequently, 9G4+ IgG concentration was highly correlated with both anti-dsDNA (p<0.001, r=0.48) and anti-chromatin (p<0.001, r=0.45) concentration in SLE patients but not in CCLE patients. CCLE patients, however, did have auto-reactive 9G4+, as B cell binding antibodies were similar between SLE and CCLE patients.

Conclusion: Our study confirms the correlation between 9G4+ IgG and anti-dsDNA in SLE and extends this to anti-chromatin. Surprisingly, CCLE patients had high levels of 9G4+ IgG but not anti-dsDNA. This suggests a two-step model of 9G4 tolerance in SLE, the breakdown of general tolerance of germline encoded autoreactive VH4.34 antibodies and a subsequent development of 9G4+ specific for dsDNA. CCLE patients clearly have a defect in the first step and the mechanism of this defect is potentially shared between CCLE and SLE. However, the second step is not shared, as CCLE patients with 9G4+ IgG do not have high levels of anti-dsDNA. Regulation of this step may help determine if otherwise immunologically similar patients may develop SLE or CCLE. Because the specificity of 9G4+ in CCLE is unknown, it remains to be determined whether these antibodies contribute directly to CCLE disease


Disclosure: S. Jenks, None; R. Bugrovsky, None; X. Wang, None; A. Hill, None; C. Wei, None; S. S. Lim, None; I. Sanz, None; C. Drenkard, None.

To cite this abstract in AMA style:

Jenks S, Bugrovsky R, Wang X, Hill A, Wei C, Lim SS, Sanz I, Drenkard C. Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/chronic-cutaneous-lupus-erythematosus-patients-have-a-breakdown-in-autoreactive-vh4-34-antibody-tolerance-while-maintaining-tolerance-to-dsdna-and-chromatin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-cutaneous-lupus-erythematosus-patients-have-a-breakdown-in-autoreactive-vh4-34-antibody-tolerance-while-maintaining-tolerance-to-dsdna-and-chromatin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology